BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given a consensus recommendation of “Moderate Buy” by the five analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $15.60.

BCRX has been the topic of several research reports. Barclays upped their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after buying an additional 375,890 shares in the last quarter. Exome Asset Management LLC acquired a new stake in BioCryst Pharmaceuticals during the third quarter worth approximately $1,493,000. Franklin Resources Inc. grew its stake in BioCryst Pharmaceuticals by 177.8% in the 3rd quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company’s stock worth $1,968,000 after acquiring an additional 168,790 shares during the period. Sanctuary Advisors LLC grew its stake in BioCryst Pharmaceuticals by 78.3% in the 3rd quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company’s stock worth $360,000 after acquiring an additional 20,818 shares during the period. Finally, SkyView Investment Advisors LLC raised its holdings in BioCryst Pharmaceuticals by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 3,000 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Down 0.1 %

BCRX stock opened at $7.71 on Friday. The company’s 50-day moving average price is $7.64 and its 200 day moving average price is $7.46. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88. The company has a market cap of $1.60 billion, a P/E ratio of -12.64 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. During the same period last year, the firm earned ($0.19) EPS. BioCryst Pharmaceuticals’s revenue was up 35.1% compared to the same quarter last year. On average, equities research analysts expect that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.